Previous Close | 1,705.00 |
Open | 1,708.00 |
Bid | 1,709.00 x 0 |
Ask | 1,711.00 x 0 |
Day's Range | 1,694.00 - 1,726.00 |
52 Week Range | 1,125.00 - 1,938.00 |
Volume | |
Avg. Volume | 584,802 |
Market Cap | 2.303B |
Beta (5Y Monthly) | -0.05 |
PE Ratio (TTM) | 1,694.00 |
EPS (TTM) | 0.01 |
Earnings Date | Feb 22, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jun 16, 2016 |
1y Target Est | 24.94 |
Subscribe to Yahoo Finance Plus to view Fair Value for INDV.L
Indivior PLC (INDV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose. The study, "Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone", was published in the Journal of Clinical Pharmacology (Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers:
Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.